.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BX05_Calcifediol.Calcifediol .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BX05_Calcifediol.Calcifediol| name: | Calcifediol |
| ATC code: | H05BX05 | route: | oral |
| n-compartments | 1 |
Calcifediol, also known as 25-hydroxyvitamin D3, is a prohormone of the active form of vitamin D. It is used in the management of vitamin D deficiency and in certain cases of chronic kidney disease to treat secondary hyperparathyroidism. The drug is approved and commonly used in clinical practice.
Reported in healthy adult subjects following single oral administration.
Ocampo-Pelland, AS, et al., & Riggs, MM (2017). Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics. Journal of pharmacokinetics and pharmacodynamics 44(4) 375–388. DOI:10.1007/s10928-017-9525-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28466367
Tuey, SM, et al., & Joy, MS (2024). Population Pharmacokinetic Model of Vitamin D. International journal of molecular sciences 25(22) –. DOI:10.3390/ijms252212279 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39596344
Hsu, S, et al., & de Boer, IH (2021). Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. Journal of the American Society of Nephrology : JASN 32(1) 188–198. DOI:10.1681/ASN.2020050625 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33115916